Adverse drug reactions after intravenous rituximab infusion are more common in hematologic malignancies than in autoimmune disorders and can be predicted by the combination of few clinical and laboratory parameters: results from a retrospective, multicenter study of 374 patients

Luca Laurenti, Idanna Innocenti, Angela Padula, Fiorella D'Auria, Giovanni D’Arena, Vittorio Simeon, Michele Cimminiello, Michele Gilio, Maria Luigia Vigliotti, Sonya De Lorenzo, Giacomo Loseto, Anna Passarelli, Matteo Nicola Dario Di Minno, Marco Tucci, Vincenzo De Feo, Fiorella D’Auria, Francesco Silvestris, Giovanni Di Minno, Pellegrino Musto

Risultato della ricerca: Contributo in rivistaArticolo in rivista

4 Citazioni (Scopus)

Abstract

Rituximab is an effective treatment for CD20 + B-cell malignancies and autoimmune disorders. However, adverse drug reactions (ADRs) may occur after rituximab infusion, causing, in rare cases, its discontinuation. In this multicenter, retrospective study, among 374 patients treated with rituximab i.v., 23.5% experienced ADRs. Mean follow-up was 20.6 months (range 8–135). Overall, ADRs were significantly more frequent in non-Hodgkin lymphomas (NHL) and chronic lymphocytic leukemias (25–35.9%), than in autoimmune diseases (9.4–17.5%) (p <.0001). Grade 3–4 toxicity was observed in eight patients (2.1%), and in four of them (1% of all patients) definitive drug discontinuation was necessary. Interestingly, three groups of patients with different risk of developing ADR were identified, according to a predictive heat-map developed combining four parameters (splenomegaly, history of allergy, hemoglobin levels and gender) selected by multivariate analysis. This model may be useful in identifying patients at higher risk of ADRs, needing appropriate preventing therapies.
Lingua originaleEnglish
pagine (da-a)2633-2641
Numero di pagine9
RivistaLEUKEMIA &amp; LYMPHOMA
Volume58
DOI
Stato di pubblicazionePubblicato - 2017

Keywords

  • Cancer Research
  • Hematology
  • Oncology
  • Rituximab
  • adverse drug reaction
  • autoimmune diseases
  • lymphoma
  • pharmacovigilance
  • rheumatoid arthritis

Fingerprint Entra nei temi di ricerca di 'Adverse drug reactions after intravenous rituximab infusion are more common in hematologic malignancies than in autoimmune disorders and can be predicted by the combination of few clinical and laboratory parameters: results from a retrospective, multicenter study of 374 patients'. Insieme formano una fingerprint unica.

Cita questo